Cited by 266Acute Lymphoblastic Leukemia researchCell death mechanisms and regulationAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Peirs, Sofie, Matthijssens, Filip, Goossens, Steven, Van de Walle, Inge, Ruggero, Katia, de Bock, Charles E., Degryse, Sandrine, Canté-Barrett, Kirsten, Briot, Delphine, Clappier, Emmanuelle, Lammens, Tim, De Moerloose, Barbara, Benoit, Yves, Poppe, Bruce, Meijerink, Jules P., Cools, Jan, Soulier, Jean, Rabbitts, Terence H., Taghon, Tom, Speleman, Frank, Van Vlierberghe, Pieter·2014·Blood

DOI 10.1182/blood-2014-05-574566

Open this paper in CoChat — free account

Abstract

Key Points: High levels of the anti-apoptotic factor BCL-2 can be therapeutically exploited by the BH3 mimetic ABT-199 in human T-ALL.

Integrity signals

Registry

Crossref · 10.1182/blood-2014-05-574566

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
GenePattern 2.0
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Acute lymphoblastic leukaemia
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588
Proposals for immunological classification of acute leukemias.
van Dongen, J. J. M. (1995) · PubMed · Cited by 543
Proposals for the immunological classification of acute leukemias.
Paietta, E. M. (1995) · PubMed · Cited by 503
The molecular basis of T cell acute lymphoblastic leukemia
Vlierberghe, P. V., & Ferrando, A. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61269 · Cited by 489
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL)
Soulier, J., Clappier, E., Cayuela, J., Régnault, A., García-Peydró, M., Dombret, H., Baruchel, A., Toribio, M. L., & Sigaux, F. (2005) · Blood · doi:10.1182/blood-2004-10-3900 · Cited by 400
Self-citation
Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia
Homminga, I., Pieters, R., Langerak, A. W., de Rooi, J. J., Stubbs, A., Verstegen, M. M. A., Vuerhard, M., Buijs-Gladdines, J. G. C. A. M., Kooi, C., Klous, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.008 · Cited by 391
Self-citation
Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience
Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., Cohen, H. J., Sallan, S. E., & Asselin, B. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.116 · Cited by 346
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Touzeau, C., Dousset, C., Gouill, S. L., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat‐Deceunynck, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 290
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J. A., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B. L., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 276
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Mérino, D., Lee, L., Breslin, K. A., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 275
Decoding and unlocking the BCL-2 dependency of cancer cells
Juin, P. P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3538 · Cited by 254
The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal
McCormack, M. P., Young, L. F., Vasudevan, S., de Graaf, C. A., Codrington, R., Rabbitts, T. H., Jane, S. M., & Curtis, D. J. (2010) · Science · doi:10.1126/science.1182378 · Cited by 242
Self-citation
Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission
Barrett, A. J., Horowitz, M. M., Pollock, B. H., Zhang, M., Bortin, M. M., Buchanan, G. R., Camitta, B. M., Ochs, J. J., Graham‐Pole, J., Rowlings, P. A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311902 · Cited by 235
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia
Vlierberghe, P. V., van Grotel, M., Tchinda, J., Lee, C., Beverloo, H. B., van der Spek, P. J., Stubbs, A., Cools, J., Nagata, K., Fornerod, M. W. J., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111872 · Cited by 226
Self-citation
ETV6 mutations in early immature human T cell leukemias
Vlierberghe, P. V., Ambesi‐Impiombato, A., Pérez-García, A., Haydu, J. E., Rigo, I., Hadler, M., Tosello, V., Gatta, G. D., Paietta, E. M., Racevskis, J., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20112239 · Cited by 214
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse
Clappier, E., Gerby, B., Sigaux, F., Delord, M., Touzri, F., Hernandez, L., Ballerini, P. F., Baruchel, A., Pflumio, F., & Soulier, J. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110105 · Cited by 203
Self-citation
ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Vandenberg, C. J., & Cory, S. (2013) · Blood · doi:10.1182/blood-2013-01-475855 · Cited by 194
Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15
Inukai, T., Kiyokawa, N., Campana, D., Coustan‐Smith, E., Kikuchi, A., Kobayashi, M., Takahashi, H., Koh, K., Manabe, A., Kumagai, M., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08955.x · Cited by 162
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia
Vlierberghe, P. V., Ambesi‐Impiombato, A., Keersmaecker, K. D., Hadler, M., Paietta, E. M., Tallman, M. S., Rowe, J. M., Forné, C., Rué, M., & Ferrando, A. A. (2013) · Blood · doi:10.1182/blood-2013-03-491092 · Cited by 160
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., Lock, R. B., & Reynolds, C. P. (2007) · Blood · doi:10.1182/blood-2007-03-080325 · Cited by 157
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
Niu, X., Wang, G., Wang, Y., Caldwell, J. T., Edwards, H. J., Xie, C., Taub, J. W., Li, C., Lin, H., & Ge, Y. (2014) · Leukemia · doi:10.1038/leu.2014.72 · Cited by 127
ABT ‐199 selectively inhibits BCL 2 but not BCL 2 L 1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
Vogler, M., Dinsdale, D. D., Dyer, M. J. S., & Cohen, G. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12457 · Cited by 105
T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.
Larson, R. C., Fisch, P., Larson, T., Lavenir, I., Langford, T., King, G., & Rabbitts, T. H. (1994) · PubMed · Cited by 95
Self-citation
The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.
Larson, R. C., Osada, H., Ta, L., Lavenir, I., & Rabbitts, T. H. (1995) · PubMed · Cited by 94
Self-citation
Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors
Zuurbier, L. C., Gutiérrez, A., Mullighan, C. G., Canté-Barrett, K., Gevaert, O., de Rooi, J., Li, Y., Smits, W. K., Buijs-Gladdines, J. G. C. A. M., Sonneveld, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090233 · Cited by 89
Self-citation
Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Suryani, S., Carol, H., Chonghaile, T. N., Frismantas, V., Sarmah, C. K., High, L. M., Bornhauser, B. C., Cowley, M. J., Szymanska, B., Evans, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0259 · Cited by 86
Notch Signaling During Human T cell Development
Taghon, T., Waegemans, E., & de Walle, I. V. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_230 · Cited by 58
Self-citation
BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines
Anderson, N. M., Harrold, I., Mansour, M. R., Sanda, T., McKeown, M. R., Nagykary, N., Bradner, J. E., Zhang, G. L., Look, A. T., & Feng, H. (2013) · Leukemia · doi:10.1038/leu.2013.377 · Cited by 52
SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL
Abdelali, R. B., Roggy, A., Leguay, T., Cieślak, A., Renneville, A., Touzart, A., Banos, A., Randriamalala, E., Caillot, D., Lioure, B., et al. (2014) · Blood · doi:10.1182/blood-2013-08-521518 · Cited by 50
BCL-2 Inhibitor Yields High Response in CLL and SLL
(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2013-178 · Cited by 15

Sorted by citations

The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.63 · Cited by 460
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Jain, N., Lamb, A. V., O'Brien, S. M., Ravandi, F., Konopleva, M. Y., Jabbour, E. J., Zuo, Z., Jorgensen, J. L., Lin, P., Pierce, S. A., et al. (2016) · Blood · doi:10.1182/blood-2015-08-661702 · Cited by 354
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 289
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Frismantas, V., Dobay, M. P., Rinaldi, A. M., Tchinda, J., Dunn, S. H., Kunz, J. B., Richter‐Pechańska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 266

See all 266

Authors: Peirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., Lammens, T., De Moerloose, B., Benoit, Y., Poppe, B., Meijerink, J. P., Cools, J., Soulier, J., Rabbitts, T. H., Taghon, T., Speleman, F., & Van Vlierberghe, P.
Affiliations: Center for Medical Genetics,
Vlaams Instituut voor Biotechnologie (BE)
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium;
John Radcliffe Hospital (GB)
Laboratory for the Molecular Biology of Leukemia, Center for Human Genetics, University of Leuven and Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium;
Erasmus MC (NL)
Inserm (FR)
Ghent University Hospital (BE)
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
Ghent University (BE)
ORCID: Peirs, Sofie
Matthijssens, Filip
Goossens, Steven
Ruggero, Katia
Degryse, Sandrine
Canté-Barrett, Kirsten
Clappier, Emmanuelle
Lammens, Tim
Poppe, Bruce
Meijerink, Jules P.
Cools, Jan
Soulier, Jean
Rabbitts, Terence H.
Taghon, Tom
Speleman, Frank
Venue: Blood
Publisher: American Society of Hematology
Published: 2014-12-11
Volume: 124
Issue: 25
Pages: 3738-3747
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2014-05-574566
OpenAlex: W2048591984
Cited by: 264
References: 44
Citations by year: 2026: 12 · 2025: 18 · 2024: 31 · 2023: 29 · 2022: 24 · 2021: 25 · 2020: 22 · 2019: 25 · 2018: 22 · 2017: 18 · 2016: 22 · 2015: 16
FWCI: 18.58
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: European Hematology Association (TRTH104)
Wellcome Trust (099246/Z/12/Z)
Agence Nationale de la Recherche (ANR-10-IBHU-0002)
Topics: Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: venetoclax, BCL-2 inhibition, BH3 mimetics, T-cell acute lymphoblastic leukemia, drug synergy, doxorubicin, L-asparaginase, dexamethasone, TLX3, HOXA, TAL1, molecular subtypes, treatment resistance
MeSH terms: Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cells, Cultured, Child, Drug Synergism, Humans, Sulfonamides, Tumor Cells, Cultured, Blotting, Western, Gene Expression Regulation, Leukemic, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Bridged Bicyclo Compounds, Heterocyclic, Jurkat Cells, Proto-Oncogene Proteins c-bcl-2, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Xenograft Model Antitumor Assays, Cell Line, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks